Axogen: The Regulatory Moat Is Becoming A Commercial Flywheel
Axogen is transforming from a niche tissue supplier into a comprehensive nerve care platform, underpinned by FDA approval, stronger reimbursement, and expanding clinical evidence. Q2 2026 revenue grew 23.1% to $69.7M, with raised full-year guidance and strong elective market traction, though gross margin declined due to product mix and biologic costs. Avance's FDA biologic approval grants 12 years of exclusivity, regulatory credibility, and improved payer coverage, positioning AXGN as a category leader with significant market opportunity.
Axogen, Inc. (AXGN) Q2 2026 Earnings Call Transcript
Axogen, Inc. (AXGN) Q2 2026 Earnings Call Transcript
AxoGen Q2 Earnings Call Highlights
AxoGen NASDAQ: AXGN reported second-quarter 2026 revenue of $69.7 million, up 23.1% from a year earlier, as demand for its Avance nerve graft and broader product portfolio increased across its target markets. The company raised its full-year revenue outlook to at least $279 million, representing growth of at least 24%, while lowering its gross-margin expectation to at least 73% due to product-mix changes tied to faster-than-expected growth in breast reconstruction.
AxoGen (AXGN) Tops Q2 Earnings and Revenue Estimates
AxoGen (AXGN) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.12 per share a year ago.
AxoGen Says Nerve Repair Strategy Intact as Reimbursement Wins Gather Steam
AxoGen NASDAQ: AXGN President and CEO Michael Dale said the company's growth strategy remains centered on developing the market for peripheral nerve repair, while recent reimbursement wins are expected to be positive but have not yet been quantified.
Axogen, Inc. (AXGN) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Axogen, Inc. (AXGN) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Axogen, Inc. (AXGN) Q1 2026 Earnings Call Transcript
Axogen, Inc. (AXGN) Q1 2026 Earnings Call Transcript
AxoGen (AXGN) Q1 Earnings Lag Estimates
AxoGen (AXGN) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.12 per share. This compares to a loss of $0.02 per share a year ago.
AxoGen (AXGN) Reports Next Week: Wall Street Expects Earnings Growth
AxoGen (AXGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AxoGen (AXGN) Surges 7.5%: Is This an Indication of Further Gains?
AxoGen (AXGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
AxoGen Says BLA Approval Secures Avance Use, Boosts Coverage Talks and Reimbursement Momentum
AxoGen (NASDAQ: AXGN) executives said a newly secured Biologics License Application (BLA) approval has preserved the company's ability to serve patients across a broad range of peripheral nerve repair needs, while also helping address remaining reimbursement and coverage barriers that have affected adoption. BLA label seen as broad, consistent with prior use CEO Mike Dale said
Axogen, Inc. (AXGN) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
Axogen, Inc. (AXGN) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
